Ask AI
ProCE Banner Activity

Mapping TROP-2–Targeted ADCs Into the NSCLC Treatment Landscape

Clinical Thought

Approval of 2 new TROP-2–targeted ADCs in NSCLC is on the horizon, but how should they be sequenced with other ADCs, and should patients be concerned about key toxicities associated with these agents? 

Released: May 02, 2024

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Gilead Sciences, Inc.

Gilead Sciences, Inc.

Disclosure

Primary Author

Luis Paz-Ares, MD, PhD

Head of Medical Oncology Department
Hospital Universitario 12 de Octubre
Associate Professor, Universidad Complutense de Madrid
Av de Andalucia s/n
Madrid, Sprain

Luis Paz-Ares, MD, PhD: consultant/advisor/speaker: AbbVie, AstraZeneca, Bayer, BeOne, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, GSK, Janssen, Lilly, Merck KGaA, Mirati, MSD, Novartis, Pfizer, PharmaMar, Regeneron, Roche, Takeda; board of directors: Altum Sequencing, Stab Therapeutics.

David Planchard, MD, PhD

Gustave Roussy
Head of Thoracic Group
Department of Medical Oncology
Villejuif, France

David Planchard, MD, PhD: consultant/advisor/speaker: AbbVie, ArriVent, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Daiichi Sankyo, GSK, Janssen, Lilly, Merck, Mirati, Novartis, Pfizer, Pierre-Fabre, Roche, Seagen, Takeda.

Helena Yu, MD

Attending
Research Director, Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Helena Yu, MD: consultant/advisor/speaker: AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Janssen, Pfizer, Systimmune, Taiho.